Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 40% Improvement Relative Risk Ventilation 60% ICU admission 40% ICU time 36% Hospitalization time 17% c19early.org/d Maghbooli et al. Vitamin D for COVID-19 RCT LATE Is late treatment with vitamin D beneficial for COVID-19? Double-blind RCT 106 patients in Iran Lower ventilation (p=0.44) and ICU admission (p=0.42), not stat. sig. Maghbooli et al., Endocrine Practice, doi:10.1016/j.eprac.2021.09.016 Favors vitamin D Favors control
Treatment with 25-hydroxyvitamin D3 (calcifediol) is associated with a reduction in the blood neutrophil-to-lymphocyte ratio marker of disease severity in patients hospitalized with COVID-19: a pilot, multicenter, randomized, placebo-controlled double blind clinical trial
Maghbooli et al., Endocrine Practice, doi:10.1016/j.eprac.2021.09.016
Maghbooli et al., Treatment with 25-hydroxyvitamin D3 (calcifediol) is associated with a reduction in the blood.., Endocrine Practice, doi:10.1016/j.eprac.2021.09.016
Oct 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 106 hospitalized patients with vitamin D levels <30ng/ml in Iran, 53 treated with calcifediol, showing that treatment was able to correct vitamin D deficiency/insufficiency, resulting in improved immune system function. Hospitalization, ICU duration, ventilation, and mortality was lower with treatment, without reaching statistical significance with the small sample size. The dosage used in this trial was much lower than other trials.
Although the 40% lower mortality is not statistically significant, it is consistent with the significant 36% lower mortality [28‑44%] from meta analysis of the 60 mortality results to date.
risk of death, 40.0% lower, RR 0.60, p = 0.72, treatment 3 of 53 (5.7%), control 5 of 53 (9.4%), NNT 26.
risk of mechanical ventilation, 60.0% lower, RR 0.40, p = 0.44, treatment 2 of 53 (3.8%), control 5 of 53 (9.4%), NNT 18.
risk of ICU admission, 40.0% lower, RR 0.60, p = 0.42, treatment 6 of 53 (11.3%), control 10 of 53 (18.9%), NNT 13.
ICU time, 36.4% lower, relative time 0.64, p = 0.20, treatment 53, control 53.
hospitalization time, 16.7% lower, relative time 0.83, p = 0.10, treatment 53, control 53.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Maghbooli et al., 13 Oct 2021, Double Blind Randomized Controlled Trial, Iran, peer-reviewed, 12 authors, dosage calcifediol 25μg daily, mean daily dose.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Journal Pre-proof Treatment with 25-hydroxyvitamin D3 (calcifediol) is associated with a reduction in the blood neutrophil-to-lymphocyte ratio marker of disease severity in patients hospitalized with COVID-19: a pilot, multicenter, randomized, placebo-controlled double blind clinical trial Zhila Maghbooli, Ph.D, Mohammad Ali Sahraian, M.D, Saeid Reza JamaliMoghadam, M.D, Asma Asadi, M.D. Azadeh zarei, Abolfazl Zendehdel, M.D, Tarlan Varzandi, M.S.c, Sara Mohammadnabi, B.D, Neda Alijani, M.D, Mehrdad Karimi, Arash Shirvani, M.D., Ph.D, Michael F. Holick, Ph.D., M.D PII: S1530-891X(21)01259-3 DOI: https://doi.org/10.1016/j.eprac.2021.09.016 Reference: EPRAC 274 To appear in: Endocrine Practice Received Date: 3 June 2021 Revised Date: 15 September 2021 Accepted Date: 15 September 2021 Please cite this article as: Maghbooli Z, Sahraian MA, Jamali-Moghadam SR, Asadi A, Azadeh zarei MD, Zendehdel A, Varzandi T, Mohammadnabi S, Alijani N, Karimi M, Shirvani A, Holick MF, Treatment with 25-hydroxyvitamin D3 (calcifediol) is associated with a reduction in the blood neutrophil-tolymphocyte ratio marker of disease severity in patients hospitalized with COVID-19: a pilot, multicenter, randomized, placebo-controlled double blind clinical trial, Endocrine Practice (2021), doi: https:// doi.org/10.1016/j.eprac.2021.09.016. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2021 Published by Elsevier Inc. on behalf of the AACE. 1 2 Title: 3 Treatment with 25-hydroxyvitamin D3 (calcifediol) is associated with a reduction in the blood 4 neutrophil-to-lymphocyte ratio marker of disease severity in patients hospitalized with COVID-19: 5 a pilot, multicenter, randomized, placebo-controlled double blind clinical trial 6 Abbreviated title: 8 Therapeutic effects of oral 25-hydroxyvitamin D3 on COVID-19 of 7 ro 9 Authors:, Zhila Maghbooli1, Ph.D., Mohammad Ali Sahraian1,M.D., Saeid Reza Jamali-Moghadam2,M.D., Asma 11 Asadi3, Azadeh zarei4 ,M.D.,Abolfazl Zendehdel5,M.D., Tarlan Varzandi1, M.S.c, Sara Mohammadnabi1, B.D., Neda 12 Alijani6,M.D., Mehrdad Karimi4, Arash Shirvani7, M.D., Ph.D., Michael F. Holick*7, Ph.D.,M.D. re -p 10 lP 13 1. Multiple..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit